Fujifilm Introduces First-of-its-Kind Transducer for On-Pump Intracardiac Echocardiography Imaging (OPIE) for Septal Myectomy
April 26 2024 - 7:45AM
FUJIFILM Healthcare Americas Corporation, a leading provider of
diagnostic and enterprise imaging solutions, announced the launch
of its first-of-kind OPIE Transducer for on-pump intracardiac
echocardiography (OPIE) for septal myectomy. Early clinical users
of the OPIE transducer will discuss how the technology helps to
evaluate the ventricular septal thickness during septal myectomy
surgery by providing real-time imaging visualization during the
104th American Association for Thoracic Surgery (AATS) meeting held
April 27-30 in Toronto, ON, Canada.
Traditionally, a cardiothoracic surgeon uses transesophageal
echocardiography (TEE) before performing septal myectomy.
Currently, TEE cannot be leveraged during cardiac bypass surgery.
Instead, a surgeon views the patient’s septal thickness via TEE
prior to performing open-heart surgery and would trim the septum –
if necessary – without real-time guidance. However, with OPIE, a
thin transducer is passed into the heart during the myectomy where
images of the patient’s septal thickness can be seen in real-time.
A study featuring Fujifilm’s OPIE Transducer highlights that the
system provides established imaging to aid in septal myectomy
procedures compared to TEE and transthoracic echocardiogram (TTE).
Real-time measurements of the interventricular septal thickness are
crucial during septal myectomy to avoid creating a ventricular
septal defect while resecting enough myocardium. The OPIE
transducer is compatible with Fujifilm’s premium ultrasound system,
the ARIETTA Precision.
“During septal myectomy, it is critical to correctly measure the
patient’s septal thickness because it can directly impact the
patient’s care pathway,” said Hideyuki Honda, vice president,
ultrasound solutions, FUJIFILM Healthcare Americas Corporation.
“Every day we pride ourselves on delivering what we believe is the
highest quality ultrasound solutions, arming cardiologists and
cardiothoracic surgeons alike with the visualization they need to
eliminate guess work in the operating room. Early clinical results
of our OPIE Transducer during a high-risk procedure like cardiac
bypass surgery are impressive, and we’re proud that the technology
is proving to provide high-quality, real-time feedback for the
surgeon.”
During the AATS annual meeting, Daniel G. Swistel, MD,
Professor, Department of Cardiothoracic Surgery at NYU Grossman
School of Medicine and Nicolas Smedira, MD, Cardiothoracic Surgeon
with the Cleveland Clinic, will discuss their clinical experience
using Fujifilm’s ARIETTA Precision with the OPIE
transducer during open heart surgery, and explain the
advantages of cardiothoracic surgeons having real-time
visualization to help assist with septal myectomy surgical
procedures. Their joint presentation is taking place on Saturday,
April 27th from 6:20-6:40 pm at the Product Technology Theatre
(Theatre 2).
In addition to the OPIE Transducer and ARIETTA Precision
Ultrasound system, Fujifilm will also demonstrate the ELUXEO
Vision, an FDA-designated Breakthrough Device that provides
real-time tissue oxygenation visualization for laparoscopic and
endoscopic applications at AATS booth #431A. Also during the AATS
annual meeting, Takeo Fujita, MD, PhD, FACS, Director, Division of
Digestive Surgical Oncology, Esophageal Surgery with the National
Cancer Center Hospital East, Japan, will discuss how the ELUXEO
Vision helps assess tissue oxygen saturation and its correlation
with indocyanine green in the gastric conduit during thoracic
esophagectomy on Monday, April 29 from 9:00-9:30 am at the Tech
Theater Session II.
*The OPIE transducer is currently available in the United States
and is pending regulatory requirements in Canada.
About FUJIFILM Healthcare Americas
Corporation
FUJIFILM Healthcare Americas Corporation is a comprehensive
healthcare company that has an extensive range of technology and
expertise in the detection, diagnosis and treatment of diseases.
Fujifilm’s innovative medical imaging portfolio includes solutions
for digital radiography, mammography, CT, MRI, ultrasound,
gastroenterology, pulmonology, endosurgery, and minimally invasive
surgery. The award-winning Synapse® Enterprise Imaging portfolio
provides healthcare professionals with the cross-departmental
imaging and data access needed to deliver a complete patient
record. Fujifilm’s AI initiative, REiLI®, combines Fujifilm’s rich
image-processing heritage with cutting-edge AI innovations to
inspire clinical confidence and combat burnout. The In-Vitro
Diagnostic portfolio provides the gold standard of molecular based
immunoassay technology for liver surveillance, cutting edge
clinical diagnostic chemicals for leading laboratories and
diagnostic chemicals for OEM white labeling products. The company
is headquartered in Lexington, Massachusetts. For more information,
please visit healthcaresolutions-us.fujifilm.com.
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of
knowledge and proprietary core technologies to deliver “Value from
Innovation” in our products and services in the business segments
of healthcare, materials, business innovation, and imaging. Our
relentless pursuit of innovation is focused on providing social
value and enhancing the lives of people worldwide. Fujifilm is
committed to responsible environmental stewardship and good
corporate citizenship. For more information about Fujifilm’s
Sustainable Value Plan 2030, click here. For the year ended March
31, 2023, the company had global revenues of approximately 2.9
trillion yen (21 billion USD at an exchange rate of 134
yen/dollar). For more information, please
visit: www.fujifilmholdings.com.
Marissa Confredo
FUJIFILM Holdings America Corporation
914-789-8526
marissa.confredo@fujifilm.com